Investor directory

Bionova Capital

Bionova Capital is a venture capital firm established in 2015 and headquartered in Lisboa, Portugal. The firm specializes in investing in early-stage and growth-stage companies within the healthcare, biotechnology, therapeutics, medical technology, and digital health sectors. Bionova Capital focuses primarily on European startups, aiming to support innovative solutions in life sciences. The firm typically invests between €200,000 and €1,000,000 per project, often taking minority stakes in the companies it supports. Founded by shareholders of Hovione, a leading pharmaceutical company, Bionova Capital leverages its industry expertise to identify and nurture groundbreaking ventures in the healthcare landscape.
http://www.bionovacapital.com
http://www.hovionecapital.com
https://www.hovione.com
https://crunchbase.com/organization/hovione
https://facebook.com/hovione.en
https://linkedin.com/company/hovionecapital
https://pitchbook.com/profiles/investor/154677-97
https://twitter.com/hovionegroup
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=592256961

Gonçalo Rebelo de Andrade

Managing Director

Peter Villax

Chairman

Past deals in Wales

SolasCure

Series A in 2021
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

SolasCure

Seed Round in 2018
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.